...testing for atherosclerosis and Phase I testing for renal diseases and AD. Two other companies, Dybly AG...
...Celgene Corp. (NASDAQ:CELG), Summit, N.J. Chroma Therapeutics Ltd., Abingdon, U.K. Constellation Pharmaceuticals Inc., Cambridge, Mass. Dybly AG...

...in Phase II testing for diabetes and in Phase I trials for Alzheimer's disease (AD). Dybly AG...
...view in atherosclerosis The study results also could help guide BET inhibitor programs in development. Dybly...
...can also induce regression of established plaques, which is more clinically relevant. Kempen said that Dybly...